Geron Co. (NASDAQ:GERN) Shares Bought by Janus Henderson Group PLC

Janus Henderson Group PLC grew its holdings in shares of Geron Co. (NASDAQ:GERN) by 140.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 22,565,846 shares of the biopharmaceutical company’s stock after purchasing an additional 13,163,889 shares during the period. Janus Henderson Group PLC’s holdings in Geron were worth $102,193,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Darwin Global Management Ltd. acquired a new stake in shares of Geron in the 2nd quarter worth approximately $106,185,000. Renaissance Technologies LLC acquired a new stake in shares of Geron in the 2nd quarter worth approximately $3,315,000. Algert Global LLC acquired a new stake in shares of Geron in the 2nd quarter worth approximately $539,000. Farallon Capital Management LLC grew its holdings in shares of Geron by 124.6% in the 2nd quarter. Farallon Capital Management LLC now owns 16,837,000 shares of the biopharmaceutical company’s stock worth $71,389,000 after acquiring an additional 9,342,000 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Geron by 152.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 915,949 shares of the biopharmaceutical company’s stock worth $3,884,000 after acquiring an additional 553,081 shares during the period. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Trading Up 1.3 %

Shares of Geron stock opened at $4.00 on Thursday. Geron Co. has a fifty-two week low of $1.64 and a fifty-two week high of $5.34. The firm has a market cap of $2.42 billion, a PE ratio of -12.50 and a beta of 0.51. The business’s fifty day moving average is $4.14 and its two-hundred day moving average is $4.33. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04.

Geron (NASDAQ:GERN) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.05. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The company had revenue of $28.27 million for the quarter, compared to analyst estimates of $18.97 million. During the same quarter in the prior year, the company posted ($0.08) EPS. The business’s revenue for the quarter was up 17138.4% compared to the same quarter last year. Analysts anticipate that Geron Co. will post -0.25 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on GERN. Needham & Company LLC restated a “buy” rating and issued a $6.00 price target on shares of Geron in a report on Friday, August 9th. Leerink Partners initiated coverage on Geron in a report on Monday, September 9th. They issued an “outperform” rating and a $7.00 price target on the stock. HC Wainwright initiated coverage on Geron in a research note on Tuesday, November 5th. They issued a “buy” rating and a $8.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $8.00 target price on shares of Geron in a research note on Thursday, August 8th. Finally, Scotiabank initiated coverage on Geron in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $7.05.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.